Sunil Healthcare Ltd

Sunil Healthcare Ltd’s stock declined sharply to a fresh 52-week low of Rs.58.4 today, marking a significant downturn amid a volatile trading session and broader market pressures. The stock’s performance contrasts with the modest recovery seen in the Sensex, underscoring sector-specific and company-level challenges.

Sunil Healthcare Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 18 Mar 2026, driven primarily by a marked improvement in valuation metrics and positive financial trends. Despite lingering concerns over long-term fundamentals and market underperformance, the company’s very attractive valuation and recent quarterly results have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Sunil Healthcare Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating, despite a challenging recent performance relative to the Sensex. This change is driven by improved price-to-earnings and price-to-book value metrics, signalling potential value for investors amid a micro-cap pharmaceutical sector landscape.

Sunil Healthcare Ltd’s shares declined to a fresh 52-week low of Rs.58.61 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has experienced sustained pressure over recent sessions, reflecting a combination of subdued financial metrics and broader market dynamics.

Sunil Healthcare Ltd’s shares declined sharply to a new 52-week low of Rs.59 on 16 Mar 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting persistent pressures on its valuation and market sentiment.

Sunil Healthcare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 02 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Sunil Healthcare Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 2 March 2026, reflecting deteriorating technical indicators, modest valuation improvements, weak financial trends, and poor quality metrics. Despite some positive quarterly earnings, the company’s long-term fundamentals and technical outlook have worsened, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

Sunil Healthcare Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, driven primarily by its current price-to-earnings (P/E) and price-to-book value (P/BV) ratios. Despite a challenging year-to-date performance relative to the Sensex, the pharmaceutical company’s valuation metrics suggest a more favourable price entry point compared to its historical averages and peer group.

Sunil Healthcare Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its valuation and technical outlook despite ongoing fundamental challenges. The change, effective from 25 February 2026, is driven by a combination of improved valuation metrics and evolving technical indicators, even as the company continues to underperform key benchmarks and faces structural financial constraints.

Sunil Healthcare Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, reflecting a nuanced change in price attractiveness amid evolving sector and peer benchmarks. Despite a modest day gain of 2.63%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a recalibration of investor sentiment within the Pharmaceuticals & Biotechnology sector.

Sunil Healthcare Ltd has seen its investment rating downgraded from Sell to Strong Sell, driven primarily by deteriorating technical indicators and a reassessment of its valuation and financial trends. Despite some positive quarterly financial results, the company’s long-term fundamentals and technical outlook have raised concerns among analysts, prompting a comprehensive review of its quality, valuation, financial trend, and technical parameters.

Sunil Healthcare Ltd has witnessed a notable change in its valuation parameters, moving from a very attractive to an attractive rating, despite a challenging recent performance relative to the Sensex. This shift in price-to-earnings and price-to-book value ratios offers investors a fresh perspective on the stock’s price attractiveness within the Pharmaceuticals & Biotechnology sector.

Sunil Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sunil Healthcare Limited, India's second-largest manufacturer of empty hard gelatin capsule shells, reported a return to profitability in Q2 FY26 with net profit of ₹1.00 crores, marking a significant turnaround from losses in the previous year. However, the micro-cap pharmaceutical company's stock has struggled, trading at ₹69.61 and down 16.13% over the past year, reflecting investor scepticism about the sustainability of this recovery.

Sunil Healthcare Ltd is rated Sell by MarketsMOJO, with this rating last updated on 14 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.